Global Head of Clinical Pharmacology and DMPK, Adlai Nortye
Cambridge affiliations
- Executive MBA, Cambridge Judge Business School (2020)
- Member of Queens’ College
Professional history
Dr Xuyang Song is the Global Head of Clinical Pharmacology and DMPK at Adlai Nortye (NASDAQ: ANL). With over 15 years of global drug development experience, he has led programmes from discovery to regulatory approval for large and small molecules in oncology and autoimmune diseases. Dr Song has played a key role in numerous IND/BLA/NDA submissions and pivotal studies, securing global regulatory approvals and supporting the successful market launches of IMFINZI and Imjudo.
His career includes serving as a Director of Clinical Pharmacology and Quantitative Pharmacology at AstraZeneca and as a research fellow at the US Food and Drug Administration (FDA). Dr Song completed his undergraduate education at Shenyang Pharmaceutical University, followed by a PhD in Pharmaceutical Science and a masters degree in Biostatistics from the University of Florida.
